Transforming Growth Factor Beta 1 as a Risk Factor for Cardiovascular Diseases in End-Stage Renal Disease Patients Treated With Peritoneal Dialysis

被引:12
|
作者
Janda, Katarzyna [1 ]
Krzanowski, Marcin [1 ]
Dumnicka, Paulina [2 ]
Kusnierz-Cabala, Beata [3 ]
Krasniak, Andrzej [1 ]
Sulowicz, Wladyslaw [1 ]
机构
[1] Jagiellonian Univ, Coll Med, Chair & Dept Nephrol, PL-31501 Krakow, Poland
[2] Jagiellonian Univ, Coll Med, Dept Med Diagnost, PL-31501 Krakow, Poland
[3] Jagiellonian Univ, Coll Med, Chair Clin Biochem, PL-31501 Krakow, Poland
关键词
common carotid artery intima-media thickness; peritoneal dialysis; transforming growth factor beta 1; CHRONIC KIDNEY-DISEASE; INTIMA-MEDIA THICKNESS; CHRONIC-HEMODIALYSIS PATIENTS; VASCULAR CALCIFICATION; ATHEROSCLEROSIS; ASSOCIATIONS; IMPACT; PLAQUE;
D O I
10.7754/Clin.Lab.2013.130337
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The aim of the study was to evaluate the relationship between the atherosclerotic changes in the carotid arteries expressed as common carotid artery intima-media thickness (CCA-IMT) with Body Mass Index (BMI), serum lipid levels, and selected inflammatory state markers in peritoneal dialysis (PD) patients. Methods: The study included 67 patients (31 female and 36 male) on PD therapy for 30.4 +/- 24.2 months. Average age of the patients was 52.9 +/- 12.5 years (ranged from 19 to 75 years). The measurement of the CCA-IMT was performed by ultrasonography evaluation. BMI was calculated using the Quetelet formula. Serum lipid levels and hsCRP were performed using routine methods. IL-6, TGF-beta 1, TNF-alpha, and hepatic growth factor (HGF) were tested with ELISA assays. Results: In univariate analysis, the strongest factor influencing CCA-IMT was age (R = 0.54; p < 0.0001). CCA-IMT correlated positively with BMI (R = 0.39; p = 0.003). Of the inflammatory markers studied, significant correlations with CCA-IMT were shown for IL-6 (R = 0.35; p = 0.009), and TGF-beta (R = 0.31; p = 0.02). In multiple regression, only In TGF-beta 1 (partial correlation coefficient = 0.29; p = 0.04) appeared to predict CCA-DIT independently of age and BMI, while IL-6 was not significant in the analysis. The regression model including age, BMI and TGF-beta 1 as independent variables, explained 43% of CCA-IMT variance. Again, age was the strongest predictor of CCA-IMT (partial correlation coefficient = 0.50). Conclusions: Increased concentration of TGF-beta 1 may be a biomarker of the development of cardiovascular diseases in patients treated with PD, as well as a prognostic factor in the evaluation of atherosclerosis progression in this group of patients.
引用
收藏
页码:1163 / 1168
页数:6
相关论文
共 50 条
  • [1] TRANSFORMING GROWTH FACTOR BETA (TGF-?) AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE IN A POPULATION OF PERITONEAL DIALYSIS PATIENTS
    Janda, Katarzyna
    Janda, Katarzyna
    Krzanowski, Marcin
    Kusnierz-Cabala, Beata
    Dumnicka, Paulina
    Krasniak, Andrzej
    Chowaniec, Eve
    Tabor-Ciepiela, Barbara
    Sulowicz, Wladyslaw
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 480 - 480
  • [2] Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically Active
    Shimada, Takashi
    Urakawa, Itaru
    Isakova, Tamara
    Yamazaki, Yuji
    Epstein, Michael
    Wesseling-Perry, Katherine
    Wolf, Myles
    Salusky, Isidro B.
    Jueppner, Harald
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (02): : 578 - 585
  • [3] The Cardiovascular Risk Factor Profiles among End-stage Renal Failure Patients Treated with Continuous Ambulatory Peritoneal Dialysis and Intermittent Hemodialysis
    Zamiah, S. A. K. Sharifah
    Draman, Che Rosle
    Seman, Mohd. Ramli
    Safhan, A. Fariz
    Rozalina, R.
    Ruzni, N. I. Nik
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2018, 29 (01) : 114 - 119
  • [4] Transforming growth factor-β1 hyperexpression in African American end-stage renal disease patients
    Suthanthiran, R
    Khanna, A
    Cukran, D
    Adhikarla, R
    Sharma, VK
    Singh, T
    August, P
    KIDNEY INTERNATIONAL, 1998, 53 (03) : 639 - 644
  • [5] Pheochromocytoma in end-stage renal disease patient treated by peritoneal dialysis
    Gorsane, Imen
    Zouaghi, Karim
    Goucha, Rim
    Bacha, Mohamed Mongi
    Hedri, Hafedh
    Khiari, Karima
    Abderrahim, Ezzedine
    Ben Abdallah, Taieb
    Ben Abdallah, Nejib
    Ben Moussa, Fatma
    Ben Maiz, Hedi
    Kheder, Adel
    NEPHROLOGIE & THERAPEUTIQUE, 2008, 4 (07): : 597 - 601
  • [6] Comparison of the risk of de novo cardiovascular disease between hemodialysis and peritoneal dialysis in patients with end-stage renal disease
    Wang, I-Kuan
    Lu, Chi-Yu
    Lin, Cheng-Li
    Liang, Chih-Chia
    Yen, Tzung-Hai
    Liu, Yao-Lung
    Sung, Fung-Chang
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 218 : 219 - 224
  • [7] Peritoneal metallothionein content in patients with end-stage renal disease on or not on peritoneal dialysis
    Alscher, DM
    Biegger, D
    Mettang, T
    Dunst, R
    Wolken, D
    Kuhlmann, U
    Fritz, P
    PERITONEAL DIALYSIS INTERNATIONAL, 2001, 21 (01): : 92 - 94
  • [8] Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease
    Sharma, Sumeet
    Farrington, Ken
    Kozarski, Robert
    Christopoulos, Christos
    Niespialowska-Steuden, Maria
    Moffat, Daniel
    Gorog, Diana A.
    EUROPEAN HEART JOURNAL, 2013, 34 (05) : 354 - +
  • [9] Asymmetric Dimethylarginine: a Novel Cardiovascular Risk Factor in End-stage Renal Disease
    Alsagaff, M. Yusuf
    Thaha, M.
    Aminuddin, M.
    Yogiantoro, R. M.
    Yogiantoro, M.
    Tomino, Y.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (01) : 340 - 349
  • [10] Nocturnal hypoxemia: A neglected cardiovascular risk factor in end-stage renal disease?
    Zoccali, C
    Mallamaci, F
    Tripepi, G
    BLOOD PURIFICATION, 2002, 20 (01) : 120 - 123